“Biktarvy” (bictegravir/emtricitabine/tenofovir alafenamide)
$153 every quarter
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a once-daily, single-tablet regimen used to treat HIV-1 infection.
Biktarvy is known for its effectiveness, convenience, and minimal drug interactions, it is the world’s best-selling HIV drug, favored for its, convenience, efficacy, safety profile, and price point.
Indications
- Treatment of HIV-1 infection in adults and children weighing ≥14 kg.
- Suitable as an initial HIV treatment or for those switching from other antiretroviral regimens.
Benefits
- Effective Viral Suppression: Helps maintain undetectable viral loads (<50 copies/mL), preventing transmission (Undetectable = Untransmittable, U=U).
- Convenience & Adherence: Single daily pill reduces pill burden, improving adherence. Minimal Drug Interactions:
- Safe alongside most common medications without complex adjustments.
- Well-tolerated: Fewer side effects compared to older HIV regimens.
- Long-term safety: Lower risk of kidney problems and bone min
Biktarvy (Gilead Sciences) is currently the world’s best-selling HIV drug, favored for its, convenience, efficacy, safety profile, and price point.
